Answers are grounded in this paper and cite their sources.
Retrospective study finds superior stroke prediction with the TriAGe+ score over the Sudbury score in acute vertigo, suggesting improved risk stratification in emergency departments.
Aim: Acute dizziness is a frequent emergency department (ED) presentation, in which stroke, although relatively infrequent, is clinically significant and remains a major diagnostic challenge. We aimed to comparatively evaluate the performance of the TriAGe+ and Sudbury scores for predicting stroke in patients presenting to the ED with acute vertigo or dizziness.Material and Methods: This retrospective study was conducted in a single center and included 256 adult patients presenting to the ED with dizziness or vertigo between 2020 and 2025 (128 stroke, 128 non-stroke). Our primary outcome was the diagnostic accuracy of the TriAGe+ and Sudbury scores for predicting stroke in this patient population. The diagnostic accuracies of the two scores were compared using Receiver operating characteristic (ROC) analysis and the DeLong test.Results: The TriAGe+ score showed superior diagnostic performance compared with the Sudbury score (AUC 0.898 vs. 0.837; ΔAUC = 0.061; p = 0.005). At an optimal cut-off of ≥7, TriAGe+ reached 75.0% (95% CI: 66.6–82.2) sensitivity and 83.6% (95% CI: 76.0–89.5) specificity, while Sudbury showed 78.9% (95% CI: 70.8–85.6) sensitivity and 74.2% (95% CI: 65.7–81.5) specificity. The exclusion power of the TriAGe+ score (≥5 points) was higher due to the negative likelihood ratio of 0.09 (95% CI: 0.04–0.18). The diagnostic power of this score (≥10 points) was also higher due to its 100% (95% CI: 97.2–100.0) specificity and 100% (95% CI: 92.6–100.0) positive predictive value.Conclusion: The TriAGe+ score outperformed the Sudbury score in predicting stroke among patients presenting to the ED with acute dizziness. A TriAGe+ score at the very-high-risk threshold showed good diagnostic accuracy for stroke in our cohort. These findings, while encouraging, require external validation in prospective ED populations before routine clinical use.
No takes yet. Share an insight, caveat, or question.
Özer et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: